Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
Clomid 50 mg Tablets.
| Pharmaceutical Form |
|---|
|
Tablet. |
Clomifene Citrate 50 mg.
| Active Ingredient | Description | |
|---|---|---|
| Clomifene |
Clomifene is a non-steroidal agent which stimulates ovulation in a high percentage of appropriately selected anovulatory women. The ovulatory response to clomifene therapy is mediated through increased output of pituitary gonadotrophins, which in turn stimulates the maturation and endocrine activity of the ovarian follicle. |
| List of Excipients |
|---|
|
Sucrose |
Base: 250 micron PVC.
Foil: 20 micron hard-tempered aluminium.
(in cardboard cartons)
Pack sizes: 30 and 100 tablets.
Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
PL 04425/5900R
Licence renewed: 29th September 1995.
| Drug | Countries | |
|---|---|---|
| CLOMID | Australia, Brazil, Estonia, France, Ireland, Japan, Malta, Netherlands, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
